TD Cowen lowered the firm’s price target on InterCure to $5 from $10 and keeps an Outperform rating on the shares. The analyst said they delivered 4Q results that were modestly below our estimates on revenues which grew 33% in the quarter while a clearing of excess wholesale inventory as international operators wind down their revenues was a drag on gross margin.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on INCR:
- InterCure Reschedules 2022 Full Year Results Conference Call
- InterCure Announces Record Fourth Quarter and Fiscal Year End 2022 Results
- InterCure Files Lawsuit Against Cann Pharmaceuticals to Recover Funds Following Failed Merger
- InterCure files suit against Cann Pharmaceuticals following failed merger